The Factor V Leiden variant and risk of chronic thromboembolic pulmonary hypertension.

Chronic thromboembolic pulmonary hypertension (CTEPH) is a devastating complication that occurs in about 3% of survivors of acute pulmonary embolism (PE) [1]. Genetic risk factors may differentiate patients with acute PE who develop CTEPH from those who do not develop CTEPH. The Factor V Leiden (FVL) and Prothrombin G20210A (PT) variants are the most common genetic risk factors for venous thromboembolism (VTE) [2, 3]. In European CTEPH patients, the frequencies of these variants are not increased compared to either patients with non-CTEPH pulmonary hypertension or healthy controls [4–7]. While this data suggests that genetic risk factors for CTEPH and PE may be distinct [8], no studies have directly compared the frequencies of these variants in patients with CTEPH and patients with acute PE who did not develop CTEPH. Footnotes This manuscript has recently been accepted for publication in the European Respiratory Journal . It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article. Conflict of interest: Dr. Dodson reports grants from Actelion Pharmaceuticals (via the Entelligence Young Investigator Program), grants from Intermountain Research and Medical Foundation, during the conduct of the study. Conflict of interest: Dr. Sumner has nothing to disclose. Conflict of interest: Dr. Carlsen has nothing to disclose. Conflict of interest: Dr. Cirulis has nothing to disclose. Conflict of interest: Dr. Wilson has nothing to disclose. Conflict of interest: Dr. Gadre has nothing to disclose. Conflict of interest: Dr. Fernandes reports personal fees from Bayer, personal fees from Bristol-Meyers-Squibb, outside the submitted work. Conflict of interest: Dr. Brown has nothing to disclose. Conflict of interest: Dr. Best has nothing to disclose. Conflict of interest: Dr. Elliott reports other from United Therapeutics, other from Lung Rx LLC, grants from Arena Pharmaceuticals, grants from Respira Therapeutics, grants from Lung Biotechnology PBC, outside the submitted work.